5–11 October 2026

Take◆◆◆◆◇  People, tested on a stand-in

Muscle-sparing add-ons to GLP-1 drugs reported muscle mass and nothing about function

◆ Funding is not validationBoth results were released by the companies developing these investigational drugs, and neither has been published. The ATR-258 study is reported as investigator-initiated.

If you are taking a GLP-1 drug, you have probably wondered whether you are losing muscle along with the fat. Companies are building add-on drugs for that worry, and one reported results this week.

The trevogrumab report says muscle loss fell during GLP-1 treatment and regain improved afterwards. How patients were assigned to treatment was not disclosed, so the finding cannot be weighed. A second drug, oral ATR-258, was given to 13 people for eight weeks with no comparison group, which can show tolerability and not benefit.

In India, FSSAI has issued notices to Dr Reddy's Laboratories and Nestlé Health Science over claims that Celevida GLP+ supports lean muscle during GLP-1 and GIP therapy. No clinical outcome data accompanies that claim in the available reporting. ^1–3

HARMSNone reported. The trevogrumab report carries no adverse-event data, which is an absence of reporting rather than a clean safety record.

WHAT WOULD MOVE THISA randomised trial in people on GLP-1 drugs showing measured strength holding up, or fewer falls, rather than a better body-composition scan.

1 clinical trial of trevogrumab added to GLP-1 therapy  ·  2 Longevity.Technology · open-label, single-arm, dose-escalation (3 doses), investigator-initiated · n = 13  ·  3 ET HealthWorld · Not a study

Move◆◆◆◇◇  People, watched

Fitness and grip strength predicted who died, in two very large groups of adults

A fitness number carries real prognostic information, which is the argument for measuring it routinely. Nothing in this week's record shows that clinicians have started to. Two large studies this week say that number carries real information.

Among 562,234 adults in a clinical exercise-testing registry, peak fitness, meaning the hardest work the body can sustain, improved ten-year death-risk prediction beyond the standard cardiovascular risk factors. These were people already referred for testing, not a general population sample. Among 10,462 UK Biobank adults tested before any cancer diagnosis, fitness and grip strength tracked with death from any cause and with survival fifteen years after diagnosis. ^4,5

HARMSNot measured. Neither study tested an exercise programme, so neither reports injuries or anything else training can cause.

WHAT WOULD MOVE THISA randomised trial in which people assigned to raise their fitness then lived longer, or stayed independent longer, than those who were not.

4 Medicine & Science in Sports & Exercise · observational cohort, clinical exercise-testing registry · n = 562,234  ·  5 Mayo Clinic Proceedings · prospective cohort study (UK Biobank) · n = 10,462

Measure  Not a study

Longevity panels went on sale at $5,500 to $45,000 a year, with no report of what buyers gained

◆ Biomarkers are not outcomesThe hospital packages and the $249 calcium scan sell measurements, and neither has been shown to change what happens to the person measured.

A longevity assessment is now something a nonprofit hospital system will sell you for $5,500 to $45,000 a year, and a coronary artery calcium scan can be bought directly for $249 with no referral. The question is whether a number you pay for changes anything.

None of these services reports what happened to the people who bought them. The reporting on the $249 scan does explain the limits of a zero calcium score, which is the right caveat and a rare one here. A third company is building software to turn test data into continuing care, which is a plan, not a result. ^6–8

HARMSNot measured. Testing people without symptoms turns up incidental findings, and those lead to further scans and procedures. Neither the hospital packages nor the calcium scan reports how often that happens to buyers.

WHAT WOULD MOVE THISA study that followed buyers of one of these panels. It would need to report what was found, what was done about it, and whether buyers ended up healthier than people who did not buy one.

6 STAT News · Not a study  ·  7–8 Longevity.Technology · Not a study

Measure◆◆◆◇◇  People, watched

Brain waste clearance was measured directly in people for the first time, and overlaps with amyloid buildup

◆ Biomarkers are not outcomesA clearance-amyloid overlap is two measurements moving together, not a measured effect on a person.

Researchers injected a contrast agent into the fluid around the brain and tracked, region by region, how well 96 people cleared it, then compared that map to where amyloid protein was building up. The two tracked together: regions clearing waste more slowly also carried more amyloid.

This is the first time this clearance process has been mapped directly in people rather than inferred from animals. Separate mouse work this week showed the channels waste normally drains through can collapse in Alzheimer's-like brains, and a rat study combined imaging with modelling of the same system. All of it points at one mechanism; none of it tests whether helping the brain clear waste changes anything a person experiences. ^9–12

HARMSNo harms data is reported for the imaging or contrast procedure in this record.

WHAT WOULD MOVE THISA trial testing whether a treatment that improves glymphatic clearance changes a real outcome, not just the clearance measurement itself.

9 bioRxiv · cross-sectional human neuroimaging (intrathecal gadolinium-based Glymphatic MRI) with transcriptomic correlation · n = 96  ·  10 bioRxiv · AD mouse model, imaging/tracer study  ·  11 bioRxiv · animal study (rats) combining optical tracer imaging with PDE-based mathematical modeling across anesthesia depths  ·  12 Review